Phathom Pharmaceuticals presents new VOQUEZNA analyses in GERD at ACG 2026 meeting
Bitget2026/10/08 12:02Phathom flagged new analyses for its GERD drug VOQUEZNA ahead of the American College of Gastroenterology 2026 meeting in Nashville. Results have not been presented yet; posters are scheduled for Oct. 11-13, with a product theater on Oct. 12. Data focus on real-world patient profiles, symptom relief across weight groups, and an economic model versus proton pump inhibitors in erosive disease. The readouts aim to support positioning in a crowded reflux market, with emphasis on where VOQUEZNA may fit in treatment decisions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phathom Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610080800PRIMZONEFULLFEED9841816) on October 08, 2026, and is solely responsible for the information contained therein.
- Phathom flagged new analyses for its GERD drug VOQUEZNA ahead of the American College of Gastroenterology 2026 meeting in Nashville.
- Results have not been presented yet; posters are scheduled for Oct. 11-13, with a product theater on Oct. 12.
- Data focus on real-world patient profiles, symptom relief across weight groups, and an economic model versus proton pump inhibitors in erosive disease.
- The readouts aim to support positioning in a crowded reflux market, with emphasis on where VOQUEZNA may fit in treatment decisions.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
Crypto prices
More
